Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyvanse
Pharma
GSK-Hengrui, Takeda, Celltrion—Fierce Pharma Asia
GSK signed a 12-asset licensing deal with Hengrui. Generic erosion on Vyvanse pulled back Takeda. Celltrion plans to buy a large U.S. facility.
Angus Liu
Aug 1, 2025 9:00am
Takeda revenue sinks on more Vyvanse-related sales woes
Jul 30, 2025 11:28am
Takeda eyes upcoming launches as Vyvanse generics hit lingers
May 8, 2025 10:36am
Astellas, AstraZeneca, Glenmark and more—Fierce Pharma Asia
Sep 6, 2024 9:00am
DEA raises production quota on Takeda's Vyvanse and its generics
Sep 4, 2024 3:24pm
Takeda's Entyvio keeps its strong IBD position despite threats
Jul 31, 2024 4:43pm
